⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DAWN News
Day One Biopharmaceuticals, Inc. Common Stock
Form 8-K
sec.gov
DAWN
Form 8-K
sec.gov
DAWN
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
globenewswire.com
DAWN
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
globenewswire.com
DAWN
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
globenewswire.com
DAWN
Day One Completes Acquisition of Mersana Therapeutics
globenewswire.com
DAWN
MRSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alexander & Baldwin, Inc. (NYSE - ALEX), United Security Bancshares (Nasdaq - UBFO), Udemy, Inc. (Nasdaq - UDMY), Mersana Therapeutics, Inc. (Nasdaq - MRSN)
globenewswire.com
ALEX
UDMY
UBFO
MRSN
COUR
CWBC
DAWN
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
DAWN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mersana Therapeutics, Inc. (Nasdaq - MRSN), Cidara Therapeutics, Inc. (Nasdaq - CDTX), Cadence Bank (NYSE – CADE)
globenewswire.com
MRSN
CDTX
CADE
DAWN
MRK
HBAN
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
globenewswire.com
DAWN